Polymer Capital Management HK LTD purchased a new stake in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 8,100 shares of the company’s stock, valued at approximately $1,041,000.
Several other hedge funds have also modified their holdings of MKGAF. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Merck KGaA during the 2nd quarter valued at approximately $4,894,000. Meiji Yasuda Asset Management Co Ltd. bought a new stake in Merck KGaA in the second quarter worth $7,946,000. Te Ahumairangi Investment Management Ltd bought a new stake in Merck KGaA in the second quarter worth $6,491,000. Mission Financial Group LLC purchased a new stake in Merck KGaA during the second quarter valued at $434,000. Finally, Burk Holdings LLC purchased a new stake in Merck KGaA during the second quarter valued at $39,000. 0.10% of the stock is owned by hedge funds and other institutional investors.
Merck KGaA Stock Performance
Merck KGaA stock opened at $163.21 on Monday. The company’s 50-day moving average price is $162.62 and its 200-day moving average price is $148.44. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The company has a market cap of $21.09 billion, a PE ratio of 24.92 and a beta of 0.96. Merck KGaA has a twelve month low of $116.68 and a twelve month high of $175.56.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Read More
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
